PDCD1 and triple-negative breast carcinoma: For example, pembrolizumab (an anti-programmed cell death protein 1 (PD-1) antibody) has been approved in combination with chemotherapy to treat both early-stage and metastatic triple-negative breast cancer (Cortes et al, 2022; Schmid et al, 2020).